On Friday, Ascena Retail Group Inc(NASDAQ:ASNA)’s shares declined -1.84% to $11.22.
ascena retail group, inc. (ASNA) declared that it has accomplished its acquisition of ANN INC. for a combination of cash and ascena stock in an accretive transaction.
With the completion of the merger, ANN INC. shares will be delisted from the NYSE and trading will cease at the close of business on Friday, August 21st. ANN INC. will continue to operate as a wholly-owned partner of ascena.
With the addition of the Ann Taylor, LOFT, and Lou & Grey brands, ascena is now one of North America’s largest and most diversified specialty apparel retailers, with $7.4 billion in trailing twelve month sales, a combined fleet of over 4,900 stores, and over 70,000 associates.
Ascena Retail Group, Inc., through its auxiliaries, operates as a specialty retailer of apparel for women, and tween girls and boys. It operates through five segments: Justice, Lane Bryant, maurices, dressbarn, and Catherines segments. The company offers apparel, accessories, footwear, intimates, wear-to-work, and casual sportswear; and lifestyle products, such as bedroom furnishings and electronics, in addition to social occasion apparel, career wear, dressy apparel, and active wear. Its principal retail brands comprise Justice, Brothers, Lane Bryant, Cacique, Right Fit, Maurices, Studio Y, Dressbarn, Catherines, Maggie Barnes, Liz&Me, and Serenada. As of September 22, 2014, the company operated about 3,900 stores in the United States and Canada. It also sells its products online.
Valeant Pharmaceuticals Intl Inc(NYSE:VRX)’s shares dropped -2.89% to $222.19.
Biotech company Pharming Group N.V. published its (unaudited) financial report for the six months ended 30 June 2015.
FINANCIAL HIGHLIGHTS
- Revenues from operations raised to €5.2 million (H1 2014: €2.5 million) as a result of substantially raised revenues from product sales of €4.1 million (€2.9 million for Q2), contrast to €1.4 million for H1 2014. Revenues from Ruconest® sales in the US amounted to €3.0 million (€2.4 million for Q2) and in the EU amounted to €1.1 million (€0.5 million for Q2).
- Gross profit raised to €2.9 million (€2.1 million for Q2) from €0.7 million in H1 2014 as a result of sales in the US and a gain on inventory impairments, reflecting the improving yields from sales in the US and direct commercialisation in the EU.
- As result of increasing costs of operations (R&D, General and Administrative and Marketing and Sales), operating result reduced by €0.7 million, to a loss of €6.1 million contrast to a €5.4 million loss for H1 2014. The enhance is mostly a result of the (non-cash) share-based compensation.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
At the end of Friday’s trade, Platform Specialty Products Corp(NYSE:PAH)‘s shares dipped -4.42% to $18.81.
Platform Specialty Products Corporation (PAH) a global, diversified specialty chemicals company, declared its financial results for the three and six months ended June 30, 2015.
For the three months ended June 30, 2015:
- Net sales for the second quarter 2015 were $675 million, an enhance of 257% contrast to $189 million in the second quarter of 2014.
- Performance Applications segment: Sales were $182 million, a decline of 4.0% from $189 million in the second quarter of 2014. On a constant currency basis, sales for this segment grew 4.5%.
- Agricultural Solutions segment: Sales were $494 million, a 17.2% decline from $596 million of pro forma as adjusted sales in the second quarter of 2014. On a constant currency basis, pro forma as adjusted sales grew 1.9%.
- Total constant currency sales for the quarter were $690 million, an enhance of 2.5% from second quarter 2014 pro forma constant currency sales of $672 million.
- Adjusted EBITDA for the second quarter 2015 was $168 million, an enhance of 248% contrast to $48 million from the year-preceding period.
Platform Specialty Products Corporation produces and sells specialty chemical products in the Americas, Asia, and Europe. The company’s Performance Materials segment manufactures and markets plating products that are used to plate holes; final finishes, which are used on printed circuit boards; circuit formation products to promote adhesion and form circuit patterns; oxides that are used in the fabrication of multilayer circuit boards; and pre-treatment and cleaning solutions.
Flextronics International Ltd. (NASDAQ:FLEX), ended its Friday’s trading session with -2.05% loss, and closed at $10.51.
Flextronics (FLEX), a leading sketch-to-scale solutions company that designs and builds intelligent products for a connected world, declared recently that it has officially changed its name to Flex, with a promise to assist the world Live smarter™.
Flex CEO Mike McNamara added, “This is a new era of rapid transition and transformation, full of new disruptive technologies and business models. Our customers are facing a future that requires connectivity and intelligence in new products from almost every industry. With our full range of services, from sketch to scale, Flex is extremely well positioned to assist customers manage these challenges and capitalize on the opportunities that arise from this transformative period.”
With its global scale and extensive physical infrastructure, Flex provides innovation, design, engineering, manufacturing and supply chain services to almost every industry, ranging from healthcare and automotive to industrial, energy, communications, enterprise computing and consumer electronics. This deep experience in multiple industries provides the Company with great intelligence and insight, improving visibility and velocity in a dynamic world.
Flextronics International Ltd. provides design, manufacturing, and supply chain services and solutions to original equipment manufacturers worldwide. The company offers innovation services, such as innovations labs for supporting customer design and product development services from early concept stages; collective innovation platform, an ecosystem of technology solutions; Lab IX startup accelerator program; centers of excellence solutions in critical areas; interconnect technology center for printed circuits; and CloudLabs that enables customers to accelerate a spectrum of cloud, converged infrastructure, and datacenter strategies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
